Difference between revisions of "Vortioxetine-doxepine"

From Psychiatrienet
Jump to: navigation, search
Line 9: Line 9:
 
* '''Day 15:''' increase dosage of doxepin.  
 
* '''Day 15:''' increase dosage of doxepin.  
 
| info =
 
| info =
* {{theorSS}}
+
* {{theorSS}}<ref>[[European Medicines Agency]] | SmPC Brintellix 5 mg. </ref>
 
}}
 
}}

Revision as of 16:50, 3 March 2015

Vortioxetine
Type Antidepressant
Group SMS
links
Medscape Vortioxetine
PubChem 9966051
PubMed Vortioxetine
Kompas (Dutch) Vortioxetine
Wikipedia Vortioxetine
Doxepin
Type antidepressant
Group TCA
links
ATC-code N06AA12
Medscape Doxepin
PubChem 3158
PubMed Doxepin
Drugs.com doxepin
Kompas (Dutch) Doxepin
Wikipedia Doxepin

Switch medication from vortioxetine to doxepine.[2] [3]

Nietinrijdenbord.png Stop vortioxetine
  • Day 1: reduce dosage of vortioxetine to 5 mg/day.
  • Day 7: stop administration of vortioxetine.
Eenrichtingbord.png Start doxepine
  • Day 8: start administration of doxepin in a normal dosage of 25 mg/day.
  • Day 15: increase dosage of doxepin.
Infobord.png More information
  • Occurrence of the serotonin syndrome is not likely, but theoretically possible, so caution is necessary.[4]
  1. 1.0 1.1 1.2 1.3 1.4 KNMP; Informatorium Medicamentorum 2023; Monografie "doxepine" (Dutch)
  2. Switches are based on literature references on this page and expert opinions of the authors. The authors have used pharmacokinetic and receptor affinity properties to determine the switch schedules
  3. Stahl, S. M. (2013). Stahl's essential psychopharmacology: Neuroscientific basis and practical applications (4th ed.). Cambridge University Press.
  4. European Medicines Agency | SmPC Brintellix 5 mg.
The editors of psychiatrienet.nl take the greatest care to provide up-to-date and accurate information on this site. Nevertheless, mistakes and omissions cannot be entirely excluded. No rights devolve from the information provided. The editors and other providers of information to this site accept no responsibility for the content of this site or for the information provided therein; neither do they accept responsibility for possible damages which may derive from the use of the information on this site or from the linked sites. The editorial board accepts no responsibility for the content of the (linked) sites, for access to them, or for the products and services on these sites, nor for the occurrence of errors, viruses, and/or disruptions in service.